Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 152

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 16C
Chunk 152
---
ITEM 16C PRINCIPAL ACCOUNTANT FEES AND SERVICES

For principal accountant fees and services, see Note 5.4 to our Audited Financial Statements included in our Annual Report 2024.

The audit opinion of Deloitte Statsautoriseret Revisionspartnerselskab (PCAOB no. 1294) is included in Item 18.

Audit Fees

Audit fees consist of fees billed for professional services rendered by the principal accountant for the audit of the registrant’s annual financial statements or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years.

Audit-Related Fees

Audit-related fees consist of assurance and related services by the principal accountant that are reasonably related to the performance of the audit or review of the registrant’s financial statements and are not reported under “ Audit Fees”. Fees for audit-related services include consultations concerning financial accounting reporting standards.

Tax Fees

Tax fees consist of fees billed for professional services rendered by the principal accountant for tax compliance, tax advice, and tax planning, including tax fees billed for tax consultations.

All Other Fees

All other fees consist of products and services provided by the principal accountant, other than the services reported in “ Audit Fees,” “ Audit-Related Fees” and “ Tax Fees”.

Fees for other services comprise fees billed for other permitted services.

Pre-Approval Policies

The Audit Committee assesses and pre-approves all audit and non-audit services provided by the principal accountant.

ITEM 16D EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

Not applicable.

Table of Contents

ITEM 16E PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

In 2024, share repurchases were conducted pursuant to two share buy-back programs. The share buy-back program announced on February 14, 2024 provided for the repurchase of up to 190,000 ordinary shares, and expired on March 15, 2024 (the “ February Share Buy-Back Program”). The share buy-back program announced on March 15, 2024 provided for the repurchase of up to DKK 3,500,000,000 worth of ordinary shares, and expired on December 16, 2024 (the “ March Share Buy-Back Program”). Genmab made purchases of its ordinary shares under the February Share Buy-Back Program in connection with covering its obligations under its RSU and